American Century Companies Inc. Lowers Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

American Century Companies Inc. trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 305,974 shares of the biotechnology company’s stock after selling 167 shares during the quarter. American Century Companies Inc. owned approximately 0.53% of Ascendis Pharma A/S worth $41,729,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Headlands Technologies LLC bought a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth $864,000. Candriam S.C.A. grew its stake in Ascendis Pharma A/S by 96.6% in the second quarter. Candriam S.C.A. now owns 195,347 shares of the biotechnology company’s stock valued at $26,640,000 after purchasing an additional 95,972 shares during the last quarter. Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares in the last quarter. Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter valued at about $205,000. Finally, Legato Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 167.6% in the 2nd quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company’s stock valued at $590,000 after buying an additional 2,708 shares in the last quarter.

Ascendis Pharma A/S Trading Up 17.1 %

ASND opened at $139.57 on Tuesday. The firm has a 50 day moving average of $132.51 and a two-hundred day moving average of $136.47. The firm has a market capitalization of $8.13 billion, a PE ratio of -14.52 and a beta of 0.63. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00.

Analyst Ratings Changes

ASND has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. Wells Fargo & Company decreased their price objective on Ascendis Pharma A/S from $277.00 to $264.00 and set an “overweight” rating for the company in a report on Wednesday, September 4th. Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a research note on Friday, May 31st. They set a “buy” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, September 4th. Finally, Citigroup dropped their price target on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $187.08.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.